COMMISSIONER LEHMAN:  Okay.  Next, I would like to
       call on Lew Engman, please.
       MR. ENGMAN:  Mr. Secretary, members of the panel,
       my name is Lew Engman.  I am the President of the Generic
       Pharmaceutical  Industry Association, which is based in
       Our members probably have the most at stake in the
       outcome of these hearings.  They have a very significant
       number of ANDAs, which are pending and have been filed with
       the FDA.
       Al Engleberg, who worked with you and others in
       helping to fashion the 1984 Act, will make our oral